BiotechTube
Anacura

Anacura

Ghent, Belgium· Est.
anacura.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2018, Anacura is a Belgian life sciences holding company that consolidates expertise in diagnostics and analytical services for drug development. Its model integrates three core operational units: Labo Nuytinck for clinical diagnostics, AnaBioTec for CMC analytical services, and OHMX.bio for multi-omics and bioinformatics. Through its Discovery Studio accelerator, Anacura extends its capabilities into early-stage biotech and medtech R&D, positioning itself as a full-spectrum partner from discovery to clinical support. The company emphasizes a personal approach, scientific integrity, and high-quality laboratory solutions.

Oncology

Technology Platform

An integrated ecosystem of specialized platforms: Labo Nuytinck (clinical diagnostics & biomarker development), AnaBioTec (CMC analytical services for Small Molecules, Biologics, Cell & Gene Therapy), OHMX.bio (multi-omics - genomics, transcriptomics, proteomics, etc. - and bioinformatics), and Discovery Studio (flexible wet-lab cellular biology and translational bioinformatics for R&D acceleration).

Opportunities

The growing demand for outsourced, specialized analytics in complex drug modalities (Cell & Gene Therapy) and for integrated multi-omics data represents a major expansion opportunity.
The Discovery Studio accelerator provides a channel to engage with and capture value from early-stage innovation, potentially generating equity stakes in future biotechs alongside service revenue.

Risk Factors

Revenue is exposed to cyclical swings in biotech R&D funding and client concentration.
The service-based model faces intense competition from large global CROs and other specialists, requiring constant innovation and differentiation.
Success depends heavily on retaining key scientific talent and effectively integrating the capabilities of its distinct subsidiaries.

Competitive Landscape

Anacura competes in fragmented but crowded markets. In diagnostics, it faces other clinical labs and large networks. In CMC analytics, it competes with specialized CDMO analytical units and niche CROs. In omics, it competes with both large sequencing service providers and academic core facilities. Its key differentiation is the integrated 'centre of excellence' model combining these disciplines under one holding company.

More companies in Diagnostics & Precision Medicine →More companies in Belgium →